A Study Comparing Iberdomide and Lenalidomide After Stem Cell Transplant for Multiple Myeloma
Phase 3
1,216
about 13 years
18+
44 sites in CO, FL, GA +15
About this study
Researchers are testing whether iberdomide or lenalidomide maintenance therapy, after autologous stem cell transplant (ASCT), is more effective in people with newly diagnosed multiple myeloma. The trial will last approximately 4 years and involve about 1200 participants.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Iberdomide
- 2.Take Lenalidomide
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
lenalidomide (Immunomodulatory drug; affects immune system and cancer cells (exact mechanism unclear))
oral (Oral Capsule)
Primary: Progression-free survival (PFS)
Secondary: Achievement of CR or better and maintaining MRD-negative status in 2 bone marrow aspirate assessments that are a minimum of 1 year apart, without any examination showing MRD positive status in between assessments, Achieving MRD negativity in participants with CR or better at any time after the date of randomization, Achieving minimal residual disease (MRD) negativity in participants with complete response (CR) or better at 12 (± 3) months of maintenance treatment, Area under the iberdomide plasma concentration-time curve within a dosing interval AUC (TAU), Best response achieved prior to progressive disease (PD), Conversion from MRD positive to MRD negative in participants with CR or better, Maximum iberdomide concentration (Cmax), Number of participants with adverse events (AEs)
Oncology